The real commercial value of Promarker D as a CDx is about to be unlocked.
Janssen could probably lift its flagging sales of Invokana by using Promarker D as it can gain more patients and restrict competition. Invokana is the only FDA approved drug for the CKD indication(see below for specific details) and by using Promarker D as a CDx, it has at least up to a 4 year advantage over competitors.
The real commercial value of Promarker D as a CDx is about to be...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
-0.020(6.15%) |
Mkt cap ! $49.87M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.5¢ | 28.5¢ | $201.7K | 642.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3253 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 57411 | 2 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |